HY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hyster-Yale is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 today. The stock is trading above key moving averages and looks technically constructive, but the business fundamentals from the latest quarter were weak, and there is a major earnings event just ahead that could move the stock sharply. Analyst sentiment has improved, but I would not call this a clear buy right now without a better entry or more evidence that the recovery is actually showing up in the upcoming quarter.
HY’s short-term trend is bullish to mildly constructive: SMA_5 is above SMA_20 and SMA_200, which supports an upward structure. MACD histogram is positive at 0.133, though it is contracting, suggesting momentum is still positive but cooling. RSI_6 at 62.624 is neutral-to-slightly bullish, not overbought. Price at 39.47 is above the pivot at 38.898 and below R1 at 40.475, so the stock is near resistance rather than at a deep entry. Near-term pattern data is mixed, with a small next-day upside expectation but weak one-week and notably negative one-month expectation.
["Analyst upgrades are positive: Northland upgraded the stock to Outperform with a $50 target, and Roth Capital raised its target to $44 and kept Buy.", "Analysts are pointing to improving bookings and a potential second-half 2026 lift-truck shipment recovery.", "Technical structure is supportive with SMA_5 > SMA_20 > SMA_200.", "Options data shows bullish positioning via low put-call ratios.", "Upcoming Q1 2026 earnings could act as a catalyst if results or guidance improve."]
["Latest quarter fundamentals were weak: revenue fell 13.52% YoY, net income dropped sharply to -$52.5M, EPS declined to -2.96, and gross margin compressed to 14.19.", "The stock has an earnings announcement on 2026-05-05 after hours, creating near-term uncertainty.", "Similarity-based trend data implies weakness over the next month, with an expected -6.81% move.", "No strong insider or hedge fund accumulation trend is present.", "No recent congress trading data or influential figure buying support is available."]
In Q4 2025, Hyster-Yale showed clear deterioration in operating performance. Revenue fell to $923.2M, down 13.52% year over year. Net income turned sharply negative at -$52.5M versus the prior year, EPS fell to -2.96, and gross margin slid to 14.19%. For a long-term beginner investor, this does not yet look like a strong fundamental turnaround, even though analysts expect improvement later in FY26/FY27.
Analyst sentiment has improved over the last few days. Northland upgraded HY to Outperform with a $50 target, citing improved bookings and confidence in a second-half 2026 recovery. Roth Capital also raised its target to $44 from $40 and kept a Buy rating, calling it a solid long-term grower with GDP-plus characteristics. Wall Street is constructive overall, but the bullish case depends on a future recovery rather than current financial strength.
